Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta‑analysis of clinical trials
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial - The Lancet Oncology
Vorinostat in single agent trials | Download Table
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells - Okubo - 2020 - Cancer Science - Wiley Online Library
Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat - Experimental Hematology
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug | Nature Biotechnology
Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance | Cell Death & Disease
Frontiers | Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi | Oncology
Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression
Targeting histone deacetylases: development of vorinostat for the treatment of cancer | Epigenomics
Delivery systems for vorinostat in cancer treatment: An updated review - ScienceDirect
Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma - Kang - 2021 - Journal of Cellular Physiology - Wiley Online Library
IJMS | Free Full-Text | Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia | HTML
Vorinostat - wikidoc
Vorinostat in solid and hematologic malignancies | Journal of Hematology & Oncology | Full Text
Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy… – Myeloma Research News
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia | Clinical Epigenetics | Full Text
References in Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial - The Lancet Oncology
Summary of Phase I vorinostat trials | Download Table
A trial of vorinostat for advanced mesothelioma | Cancer Research UK
Development of vorinostat: current applications and future perspectives for cancer therapy. | Semantic Scholar
